Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension (D1AMOND)

Conditions

Children's Health | Mental Health & Behavioral Research

Phase II

Volunteers
Health Professionals

What is the purpose of this trial?

This study is an international, multicenter, open-label, long term extension study evaluating the safety of ecopipam tablets for the treatment of children and adolescent subjects with Tourette Syndrome.

Ages
6 years - 18 years
Gender
Both

Find out more about who can participate in this trial

Trial with
Emalex Biosciences, Inc.
Start Date
08/04/2021
End Date
10/31/2022

For more information about this study, contact:

David Zakur

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Michael Bloch, MD, MS
Associate Professor in the Child Study Center; Co-Director and Co-Founder of the Pediatric Depression Clinic, Child Study Center; Co-Director of the T32 Postdoctoral Research Fellowship in Childhood Neuropsychiatric Disorders, Child Study Center; Associate Director, Albert J. Solnit Integrated Training Program, Child Study Center; Co-Director of the Tic and OCD Program, Child Study Center

Sub-Investigator

Angie Landeros-Weisenberger, MD

Last Updated
04/05/2022
Study HIC
#2000027699

Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension (D1AMOND)

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigator

Contact Information